(Q38193873)

30 August 2017

1 reference

title

Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause (English)

1 reference

30 August 2017

1

Sebastian Mirkin

1 reference

30 August 2017

Barry Komm

2

1 reference

PubMed ID

24601804

30 August 2017

James H Pickar

series ordinal

3

1 reference

PubMed ID

24601804

30 August 2017

language of work or name

1 reference

1 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

10

1 reference

30 August 2017

2

1 reference

30 August 2017

135-146

1 reference

Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms

30 August 2017

1 reference

Climacteric complaints in the community.

21 January 2018

1 reference

Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age.

21 January 2018

1 reference

Hot flashes: epidemiology and physiology

21 January 2018

1 reference

Prevalence of hot flushes and night sweats around the world: a systematic review

21 January 2018

1 reference

Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis.

21 January 2018

1 reference

Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review

21 January 2018

1 reference

Undertreatment of menopausal symptoms and novel options for comprehensive management

21 January 2018

1 reference

The 2012 hormone therapy position statement of: The North American Menopause Society

21 January 2018

1 reference

Hormone therapy and endometrial angiogenesis

21 January 2018

1 reference

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

21 January 2018

1 reference

Breast cancer and hormone-replacement therapy in the Million Women Study

21 January 2018

1 reference

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

21 January 2018

1 reference

The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

21 January 2018

1 reference

An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis

21 January 2018

1 reference

A new approach to menopausal therapy: the tissue selective estrogen complex

21 January 2018

1 reference

The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention

21 January 2018

1 reference

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

21 January 2018

1 reference

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial

21 January 2018

1 reference

Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women

21 January 2018

1 reference

Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.

21 January 2018

1 reference

Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial

21 January 2018

1 reference

Tissue-selective estrogen complexes for postmenopausal women

21 January 2018

1 reference

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial

21 January 2018

1 reference

Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.

21 January 2018

1 reference

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis

21 January 2018

1 reference

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

21 January 2018

1 reference

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis

21 January 2018

1 reference

The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis

21 January 2018

1 reference

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials

21 January 2018

1 reference

Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism

21 January 2018

1 reference

The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/WHE.13.75

1 reference

30 August 2017

1 reference

PubMed ID

24601804